Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
nab-paclitaxel plus carboplatin as first-line therapy in epithelial ovarian, tubal, and primary peritoneal cancer (phase II, single-arm)
ChiCTR2000039581Phase 2Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Nov 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and carboplatin in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Objective response rate. Started Nov 2020; status: recruiting.
02
Drugs
paclitaxelcarboplatin
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2000039581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039581.